• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病 1 型发病中的晚期糖基化终产物与炎症。

Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development.

机构信息

Glycation and Diabetes Complications Group, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba 4102, Australia.

School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Australia.

出版信息

Cells. 2022 Nov 4;11(21):3503. doi: 10.3390/cells11213503.

DOI:10.3390/cells11213503
PMID:36359899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9657002/
Abstract

Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host's immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with increasing prevalence of T1D in genetically stable populations, highlighting an environmental component, consumption of advanced glycation end products (AGEs) commonly found in in Western diets has increased significantly over the past decades. AGEs can bind to cell surface receptors including the receptor for advanced glycation end products (RAGE). RAGE has proinflammatory roles including in host-pathogen defense, thereby influencing immune cell behavior and can activate and cause proliferation of immune cells such as islet infiltrating CD8 and CD4 T cells and suppress the activity of T regulatory cells, contributing to β-cell injury and hyperglycemia. Insights from studies of individuals at risk of T1D have demonstrated that progression to symptomatic onset and diagnosis can vary, ranging from months to years, providing a window of opportunity for prevention strategies. Interaction between AGEs and RAGE is believed to be a major environmental risk factor for T1D and targeting the AGE-RAGE axis may act as a potential therapeutic strategy for T1D prevention.

摘要

1 型糖尿病(T1D)是一种自身免疫性疾病,其中胰腺的β细胞受到宿主免疫系统的攻击,最终导致高血糖。它是一种复杂的多因素疾病,据推测是由遗传和环境因素共同作用的结果。在遗传稳定的人群中,T1D 的患病率不断增加,这突出了环境因素的作用,同时,在过去几十年中,西方饮食中常见的晚期糖基化终产物(AGEs)的摄入量显著增加。AGEs 可以与细胞表面受体结合,包括晚期糖基化终产物受体(RAGE)。RAGE 具有促炎作用,包括在宿主-病原体防御中,从而影响免疫细胞的行为,并可激活和引起胰岛浸润的 CD8 和 CD4 T 细胞等免疫细胞的增殖,并抑制 T 调节细胞的活性,导致β细胞损伤和高血糖。对处于 T1D 风险中的个体的研究表明,从出现症状到诊断的进展可以有所不同,从数月到数年不等,为预防策略提供了机会之窗。AGEs 与 RAGE 的相互作用被认为是 T1D 的一个主要环境风险因素,靶向 AGE-RAGE 轴可能是 T1D 预防的一种潜在治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e5/9657002/f640add88cab/cells-11-03503-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e5/9657002/f640add88cab/cells-11-03503-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e5/9657002/f640add88cab/cells-11-03503-g004.jpg

相似文献

1
Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development.糖尿病 1 型发病中的晚期糖基化终产物与炎症。
Cells. 2022 Nov 4;11(21):3503. doi: 10.3390/cells11213503.
2
Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes.靶向 1 型糖尿病中的晚期糖基化终产物受体(RAGE)。
Med Res Rev. 2020 Jul;40(4):1200-1219. doi: 10.1002/med.21654. Epub 2020 Feb 28.
3
Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.晚期糖基化终产物作为 1 型糖尿病发展的环境风险因素。
Curr Drug Targets. 2012 Apr;13(4):526-40. doi: 10.2174/138945012799499758.
4
The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.晚期糖基化终末产物受体驱动1型糖尿病中的T细胞存活和炎症反应。
J Immunol. 2016 Oct 15;197(8):3076-3085. doi: 10.4049/jimmunol.1600197. Epub 2016 Sep 21.
5
Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.1型糖尿病发病机制中的晚期糖基化终末产物受体(RAGE)
Curr Diab Rep. 2016 Oct;16(10):100. doi: 10.1007/s11892-016-0782-y.
6
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.糖基化终产物与糖尿病:机制与展望。
Biomolecules. 2022 Apr 4;12(4):542. doi: 10.3390/biom12040542.
7
Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.绝经后女性中晚期糖基化终末产物与心血管疾病的关系
Reprod Sci. 2015 Jul;22(7):774-82. doi: 10.1177/1933719114549845. Epub 2014 Sep 16.
8
Tetrahedral Framework Nucleic Acids Based Small Interfering RNA Targeting Receptor for Advanced Glycation End Products for Diabetic Complications Treatment.基于四面体框架核酸的小分子干扰 RNA 靶向晚期糖基化终产物受体治疗糖尿病并发症。
ACS Nano. 2023 Nov 28;17(22):22668-22683. doi: 10.1021/acsnano.3c06999. Epub 2023 Sep 26.
9
Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.衰老相关、非传染性慢性炎症性疾病中的晚期糖基化终产物及其受体;临床证据概述及对疾病的潜在贡献。
Int J Biochem Cell Biol. 2016 Dec;81(Pt B):403-418. doi: 10.1016/j.biocel.2016.06.016. Epub 2016 Jun 29.
10
Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions.晚期糖基化终产物(AGEs)、谷胱甘肽与乳腺癌:因素、机制与治疗干预。
Curr Drug Metab. 2019;20(1):65-71. doi: 10.2174/1389200219666180912104342.

引用本文的文献

1
Interplay of hypoxia, immune dysregulation, and metabolic stress in pathophysiology of type 1 diabetes.1型糖尿病病理生理学中缺氧、免疫失调和代谢应激的相互作用
Front Immunol. 2025 Jun 4;16:1599321. doi: 10.3389/fimmu.2025.1599321. eCollection 2025.
2
Type 1 diabetes mellitus prevention: present and future.1型糖尿病的预防:现状与未来。
Nat Rev Endocrinol. 2025 Jun 17. doi: 10.1038/s41574-025-01128-6.
3
Exercise Empowerment: A Multifaceted Anatomy in Managing Diabetic Myocardial Disorder.运动赋能:管理糖尿病性心肌病的多维度剖析

本文引用的文献

1
Pathophysiology of RAGE in inflammatory diseases.晚期糖基化终末产物受体(RAGE)在炎症性疾病中的病理生理学。
Front Immunol. 2022 Jul 29;13:931473. doi: 10.3389/fimmu.2022.931473. eCollection 2022.
2
Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children - From Disease Pathogenesis to Complications.肥胖症对儿童 1 型糖尿病的多方面影响——从疾病发病机制到并发症。
Front Endocrinol (Lausanne). 2022 Jun 16;13:890833. doi: 10.3389/fendo.2022.890833. eCollection 2022.
3
Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells.
J Cardiovasc Transl Res. 2025 Jun 4. doi: 10.1007/s12265-025-10630-1.
4
gene polymorphism (rs1800625) and type 1 diabetes mellitus: A potential new model for early diagnosis and risk prediction.基因多态性(rs1800625)与1型糖尿病:早期诊断和风险预测的潜在新模型
Narra J. 2025 Apr;5(1):e1603. doi: 10.52225/narra.v5i1.1603. Epub 2025 Jan 30.
5
Role of the receptor for advanced glycation end products in the severity of SARS-CoV-2 infection in diabetic patients.晚期糖基化终末产物受体在糖尿病患者感染严重急性呼吸综合征冠状病毒2中的作用。
Diabetol Int. 2024 Jul 26;15(4):732-744. doi: 10.1007/s13340-024-00746-1. eCollection 2024 Oct.
6
Facilitation of diabetic wound healing by far upstream element binding protein 1 through augmentation of dermal fibroblast activity.远上游元件结合蛋白1通过增强真皮成纤维细胞活性促进糖尿病伤口愈合。
Acta Diabetol. 2025 Mar;62(3):353-365. doi: 10.1007/s00592-024-02360-8. Epub 2024 Oct 16.
7
Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation.评估持续血糖监测对1型糖尿病患者勃起功能障碍的影响:聚焦于降低血糖变异性和炎症反应
Healthcare (Basel). 2024 Sep 12;12(18):1823. doi: 10.3390/healthcare12181823.
8
CORM-3 Inhibits the Inflammatory Response of Human Periodontal Ligament Fibroblasts Stimulated by LPS and High Glucose.一氧化碳释放分子-3抑制脂多糖和高糖刺激的人牙周膜成纤维细胞的炎症反应。
J Inflamm Res. 2024 Jul 22;17:4845-4863. doi: 10.2147/JIR.S460954. eCollection 2024.
9
Unveiling potential therapeutic targets for diabetes-induced frozen shoulder through Mendelian randomization analysis of the human plasma proteome.通过人类血浆蛋白质组的孟德尔随机化分析揭示糖尿病性冻结肩的潜在治疗靶点。
BMJ Open Diabetes Res Care. 2024 May 7;12(3):e003966. doi: 10.1136/bmjdrc-2023-003966.
10
The analgesic effects of insulin and its disorders in streptozotocin-induced short-term diabetes.链脲佐菌素诱导的短期糖尿病中胰岛素及其紊乱的镇痛作用。
Physiol Rep. 2024 Apr;12(8):e16009. doi: 10.14814/phy2.16009.
可溶性 RAGE 可防止 1 型糖尿病扩增功能性调节性 T 细胞。
Diabetes. 2022 Sep 1;71(9):1994-2008. doi: 10.2337/db22-0177.
4
The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort from the US using the Cerner Real-World Data.COVID-19 诊断、1 型糖尿病与糖尿病酮症酸中毒风险之间的关联:来自美国 Cerner 真实世界数据的全国性队列研究。
PLoS One. 2022 Apr 19;17(4):e0266809. doi: 10.1371/journal.pone.0266809. eCollection 2022.
5
CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate.CD36,一种信号受体和脂肪酸转运蛋白,调节免疫细胞代谢和命运。
J Exp Med. 2022 Jun 6;219(6). doi: 10.1084/jem.20211314. Epub 2022 Apr 19.
6
Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot.Galectin-3 在糖尿病及其并发症中的新兴作用:快照。
Rev Endocr Metab Disord. 2022 Jun;23(3):569-577. doi: 10.1007/s11154-021-09704-7. Epub 2022 Jan 27.
7
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges.成人起病型 1 型糖尿病:当前认识与挑战。
Diabetes Care. 2021 Nov;44(11):2449-2456. doi: 10.2337/dc21-0770.
8
Natural Killer Cells as Key Mediators in Type I Diabetes Immunopathology.自然杀伤细胞作为 I 型糖尿病免疫病理学的关键介质。
Front Immunol. 2021 Aug 20;12:722979. doi: 10.3389/fimmu.2021.722979. eCollection 2021.
9
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.低剂量白细胞介素 2 和调节性 T 细胞过继细胞疗法在 1 型糖尿病患者中的作用。
JCI Insight. 2021 Sep 22;6(18):e147474. doi: 10.1172/jci.insight.147474.
10
Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes.在 1 型糖尿病中打破和恢复对胰岛β细胞的免疫耐受。
Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):397-403. doi: 10.1097/MED.0000000000000646.